Fasting-Mimicking Diet Provides Real Relief in New Crohn’s Disease Clinical Trial
A clinical trial led by Dr. Sidhartha Sinha at Stanford University involving 97 Crohn’s disease patients across the U.S. found that a fasting-mimicking diet improved symptoms and remission rates, the study published January 13 in *Nature Medicine* showed. The five-day monthly low-calorie, plant-based diet led to symptom improvement in 69% of participants compared to 44% in the control group, according to the researchers.
The trial assigned 65 patients to the fasting-mimicking diet (FMD) group and 32 to a control group that continued their usual diet and medications for three months, according to the study published January 13 in *Nature Medicine*. The FMD involved a five-day monthly regimen of low-calorie, plant-based meals ranging from 700 to 1,100 calories daily, while the control group maintained their normal eating patterns throughout the study period, officials said.
“Results showed that 69% of patients in the FMD group experienced symptom improvement compared to 44% in the control group, the researchers reported.”
Results showed that 69% of patients in the FMD group experienced symptom improvement compared to 44% in the control group, the researchers reported. Clinical remission, defined as symptoms nearly or completely disappearing, was achieved in 65% of the FMD participants versus 38% of those in the control group. About two-thirds of the FMD group reported symptom improvements by the end of the trial, according to Dr. Sidhartha Sinha, assistant professor of gastroenterology and hepatology at Stanford University and lead investigator of the study.
Dr. Sinha noted that benefits were observed even after a single cycle of the fasting-mimicking diet. “We noticed that even after just one fasting-mimicking diet cycle, there were clinical benefits,” he said in a statement. He added that the diet’s effects on inflammatory markers made it a promising intervention for Crohn’s disease, which is characterized by elevated inflammation.
The study also documented significant declines in fecal calprotectin, a biomarker of gut inflammation, among patients following the FMD compared to controls. In addition, the FMD group showed reductions in inflammation-promoting lipid mediators derived from fatty acids, and their immune cells produced fewer inflammatory molecules, the researchers said. Previous research cited by the team indicated that the fasting-mimicking diet lowers C-reactive protein levels among patients with high baseline inflammation, further supporting its potential anti-inflammatory effects.
No serious adverse events were reported during the trial, although some participants in the FMD group experienced fatigue and headaches, according to the study authors. The control group maintained their usual diet and continued Crohn’s medications throughout the trial, which the researchers suggested could explain some symptom improvements seen in that group due to natural disease fluctuations.
The study enrolled 97 patients with mild-to-moderate Crohn’s disease from multiple locations across the United States, according to the Stanford Medicine news release issued in January 2026. The trial was conducted over three consecutive months, with the fasting-mimicking diet administered for five days each month.
Dr. Sinha emphasized the simplicity of the intervention, describing it as a low-calorie, plant-based diet that patients could incorporate monthly. “We were very pleasantly surprised that the majority of patients seemed to benefit from this diet,” he said.
Researchers involved in the trial are now exploring changes in the gut microbiome as a possible mechanism underlying the observed clinical improvements, according to a ScienceDaily article summarizing the Stanford study in April 2026. The trial’s findings address a gap in clear dietary guidance for Crohn’s disease, which affects millions of people worldwide and often involves fluctuating symptoms and inflammation.
Additional coverage in *Gastroenterology Advisor* and Powers Health news confirmed the improved response and remission rates associated with the fasting-mimicking diet, highlighting its potential as a new dietary option for managing mild-to-moderate Crohn’s disease. The study’s publication in *Nature Medicine* marks a significant contribution to research on non-pharmacologic interventions for inflammatory bowel diseases.
The trial’s results provide clinical and mechanistic evidence supporting the fasting-mimicking diet as a viable adjunct therapy for Crohn’s disease, according to the authors. Further research is underway to better understand the long-term effects of the diet and its impact on the gut microbiome and immune system.
